levofloxacin has been researched along with ketotifen in 5 studies
| Studies (levofloxacin) | Trials (levofloxacin) | Recent Studies (post-2010) (levofloxacin) | Studies (ketotifen) | Trials (ketotifen) | Recent Studies (post-2010) (ketotifen) |
|---|---|---|---|---|---|
| 4,346 | 581 | 2,209 | 1,212 | 275 | 151 |
| Protein | Taxonomy | levofloxacin (IC50) | ketotifen (IC50) |
|---|---|---|---|
| 5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | 0.16 | |
| Muscarinic acetylcholine receptor M2 | Homo sapiens (human) | 0.838 | |
| Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | 1.009 | |
| Muscarinic acetylcholine receptor M5 | Homo sapiens (human) | 0.374 | |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | 2.187 | |
| Muscarinic acetylcholine receptor M1 | Homo sapiens (human) | 1.112 | |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | 0.71 | |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 2.537 | |
| Muscarinic acetylcholine receptor M3 | Homo sapiens (human) | 2.209 | |
| D(1A) dopamine receptor | Homo sapiens (human) | 0.872 | |
| Histamine H2 receptor | Homo sapiens (human) | 4.129 | |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | 3.727 | |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 0.031 | |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 0.16 | |
| 5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | 2.537 | |
| Histamine H1 receptor | Homo sapiens (human) | 0.0011 | |
| D(3) dopamine receptor | Homo sapiens (human) | 1.963 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.046 | |
| 5-hydroxytryptamine receptor 6 | Homo sapiens (human) | 1.141 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Barber, J; Dawson, S; Kenna, JG; Paul, N; Stahl, S | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
5 other study(ies) available for levofloxacin and ketotifen
| Article | Year |
|---|---|
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Cholestasis; Drug-Related Side Effects and Adverse Reactions; Humans; Insecta; Rats; Risk Factors | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |